Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 7
Safety Considerations for CAR T-Cell Therapy in R/R DLBCL
Experts discuss strategies for monitoring and managing cytokine release syndrome (CRS) and neurotoxicity, the influence of key takeaways from cohorts 4 and 6 of the ZUMA-1 trial on their practice, and how post- chimeric antigen receptor T-cell therapy (CAR T) follow-up care is managed between academic and community settings.
Video content above is prompted by the following:
- What are your strategies for monitoring and managing CRS and neurotoxicity?
- How did the key takeaways from cohorts 4 and 6 of the ZUMA-1 trial influence your practice?
- How do you manage post–CAR T follow-up care between academic and community settings?
Related Content:
